Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Fernandez, J. Ritter, J. Goodwin, D. Linehan, W. Hawkins, S. Strasberg (2005)Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Journal of the American College of Surgeons, 200 6
R. Ezekowitz, J. Mulliken, J. Folkman (1992)Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy
International Journal of Gynecology & Obstetrics, 40
H. Ohtani (2007)Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer.
Cancer immunity, 7
G. Masi, F. Loupakis, L. Salvatore, L. Fornaro, C. Cremolini, S. Cupini, A. Ciarlo, F. Monte, E. Cortesi, D. Amoroso, C. Granetto, G. Fontanini, E. Sensi, C. Lupi, M. Andreuccetti, A. Falcone (2010)Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
The Lancet. Oncology, 11 9
(2012)Perioperative chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer; a multicenter, single arm phase I/II trial: ASSO LM1
M. Saif (2009)Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
World journal of gastroenterology, 15 31
P. Chaudhury, M. Hassanain, N. Bouganim, A. Salman, P. Kavan, P. Metrakos (2010)Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
HPB : the official journal of the International Hepato Pancreato Biliary Association, 12 1
E. Giovannucci, K. Wu (2006)Cancers of the Colon and Rectum
Y. Takebayashi, S. Akiyama, Kazutaka Yamada, S. Akiba, T. Aikou (1996)Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma
D. Parkin, F. Bray, J. Ferlay, P. Pisani (2005)Global Cancer Statistics, 2002
CA: A Cancer Journal for Clinicians, 55
B Nordlinger, M Guiguet, JC Vaillant, P Balladur, K Boudjema, P Bachellier (1996)Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients: Association Fran�aise de Chirurgie
Y. Fong, J. Fortner, Ruth Sun, M. Brennan, L. Blumgart (1999)Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.
Annals of surgery, 230 3
(2004)as an isoform - specific receptor for vascular endothelial growth factor
for Diagnostics (2005)REporting recommendations for tumor MARKer prognostic studies (REMARK)
Nature Clinical Practice Oncology, 2
G. Chong, D. Cunningham (2005)Improving long-term outcomes for patients with liver metastases from colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 36
O. Stoeltzing, Wenbiao Liu, N. Reinmuth, A. Parikh, S. Ahmad, Y. Jung, F. Fan, L. Ellis (2003)Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis.
Annals of surgical oncology, 10 7
R. Wahl, H. Jacene, Y. Kasamon, M. Lodge (2009)From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Journal of Nuclear Medicine, 50
D. Ribero, Huamin Wang, M. Donadon, D. Zorzi, M. Thomas, C. Eng, D. Chang, S. Curley, E. Abdalla, L. Ellis, J. Vauthey (2007)Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases
A. Pool, Z. Lalmahomed, J. Wilt, A. Eggermont, J. Ijzermans, C. Verhoef (2009)Local Treatment for Recurrent Colorectal Hepatic Metastases after Partial Hepatectomy
Journal of Gastrointestinal Surgery, 13
M. Rees, P. Tekkis, F. Welsh, T. O’Rourke, T. John (2008)Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer: A Multifactorial Model of 929 Patients
Annals of Surgery, 247
A. Okines, O. Puerto, D. Cunningham, I. Chau, E. Cutsem, L. Saltz, J. Cassidy (2009)Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
British Journal of Cancer, 101
A. Brouquet, M. Mortenson, J. Vauthey, M. Rodriguez-Bigas, M. Overman, G. Chang, S. Kopetz, C. Garrett, S. Curley, E. Abdalla (2010)Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?
Journal of the American College of Surgeons, 210 6
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, D. Forman (2011)Global cancer statistics
CA: A Cancer Journal for Clinicians, 61
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
European journal of cancer, 45 2
J. Knowelden (1976)Cancer Epidemiology and Prevention
British Journal of Cancer, 33
V. Artigas, G. Marín-Hargreaves, E. Marcuello, A. Pey, J. González, M. Rodríguez, A. Moral, J. Monill, José Sancho, C. Pericay, M. Trías (2007)[Surgical resection of liver metastases from colorectal carcinoma. Experience in Sant Pau Hospital].
Cirugia espanola, 81 6
J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem, F. Rivera, I. Kocáková, P. Ruff, M. Błasińska-Morawiec, M. Šmakal, J. Canon, M. Rother, K. Oliner, Ying Tian, F. Xu, R. Sidhu (2014)Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 25 7
ML Gagnon, DR Bielenberg, Z Gechtman, HQ Miao, S Takashima, S Soker (2000)Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity
Proc Natl Acad Sci U S A, 97
(2012)PD-0004 Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer; A Multicenter, Single Arm Phase I/II Trial: Asso Lm1
B. Nordlinger, M. Guiguet, J. Vaillant, P. Balladur, K. Boudjema, P. Bachellier, D. Jaeck, Association Chirurgie (1996)Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients
E. Cutsem, J. Tabernero, R. Lakomy, H. Prenen, J. Prausová, T. Macarulla, P. Ruff, G. Hazel, V. Moiseyenko, D. Ferry, J. Mckendrick, J. Polikoff, A. Tellier, R. Castan, C. Allegra (2012)Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 28
T. Pawlik, R. Schulick, M. Choti (2008)Expanding criteria for resectability of colorectal liver metastases.
The oncologist, 13 1
B. Aussilhou, S. Dokmak, S. Faivre, V. Paradis, V. Vilgrain, J. Belghiti (2009)Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab
Annals of Surgical Oncology, 16
J. Holash, S. Davis, N. Papadopoulos, S. Croll, L. Ho, M. Russell, P. Boland, Raymond Leidich, D. Hylton, E. Burova, E. Ioffe, Tammy Huang, C. Radziejewski, Kevin Bailey, J. Fandl, T. Daly, S. Wiegand, G. Yancopoulos, J. Rudge (2002)VEGF-Trap: A VEGF blocker with potent antitumor effects
Proceedings of the National Academy of Sciences of the United States of America, 99
R Vera, J Figueras, M Gomez Dorronsoro, S Lopez Ben, A Viudez, B Queralt (2012)Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab: Updated findings
J Clin Oncol, 30
Yutaka Takahashi, Y. Kitadai, C. Bucana, K. Cleary, L. Ellis (1995)Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.
Cancer research, 55 18
A. Jemal, F. Bray, Melissa Center, J. Ferlay, Elizabeth Ward, D. Forman (2011)Global Cancer Statistics
K. Kim, Bing Li, J. Winer, M. Armanini, N. Gillett, H. Phillips, N. Ferrara (1993)Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
D. Parkin (2004)International variation
Y. Chun, J. Vauthey, Piyaporn Boonsirikamchai, D. Maru, S. Kopetz, M. Palavecino, S. Curley, E. Abdalla, H. Kaur, C. Charnsangavej, E. Loyer (2009)Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
JAMA, 302 21
R. Wong, D. Cunningham, Y. Barbáchano, C. Saffery, J. Valle, T. Hickish, S. Mudan, G. Brown, Adeel Khan, A. Wotherspoon, A. Strimpakos, Janet Thomas, S. Compton, Y. Chua, I. Chau (2011)A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Annals of oncology : official journal of the European Society for Medical Oncology, 22 9
D. Blazer, Y. Kishi, D. Maru, S. Kopetz, Y. Chun, M. Overman, D. Fogelman, C. Eng, D. Chang, Huamin Wang, D. Zorzi, D. Ribero, L. Ellis, K. Glover, R. Wolff, S. Curley, E. Abdalla, J. Vauthey (2008)Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 33
M. Klinger, D. Tamandl, Sandra Eipeldauer, S. Hacker, B. Herberger, K. Kaczirek, M. Dorfmeister, B. Gruenberger, T. Gruenberger (2010)Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX
Annals of Surgical Oncology, 17
L. Rubbia-Brandt, E. Giostra, C. Brézault, Arnaud Roth, Axel Andres, V. Audard, P. Sartoretti, Bertrand Dousset, P. Majno, Olivier Soubrane, S. Chaussade, Gilles Mentha, Benoît Terris (2006)Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
Annals of oncology : official journal of the European Society for Medical Oncology, 18 2
D. Schottenfeld, J. Fraumeni (2006)Cancer epidemiology and prevention.
Peter Vermeulen, G. Eynden, P. Huget, G. Goovaerts, J. Weyler, F. Lardon, E. Marck, Guy Hubens, Luc Dirix (1999)Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer
British Journal of Cancer, 79
R. Haas, D. Wicherts, P. Andreani, G. Pascal, F. Saliba, P. Ichai, R. Adam, D. Castaing, D. Azoulay (2011)Impact of Expanding Criteria for Resectability of Colorectal Metastases on Short- and Long-Term Outcomes After Hepatic Resection
Annals of Surgery, 253
E. Botteri, S. Iodice, V. Bagnardi, S. Raimondi, A. Lowenfels, P. Maisonneuve (2017)Smoking and Colorectal Cancer
Melissa Center, A. Jemal, Elizabeth Ward (2009)International Trends in Colorectal Cancer Incidence Rates
Cancer Epidemiology Biomarkers & Prevention, 18
(2015)the New EPOC randomised controlled trial
B. Gruenberger, D. Tamandl, J. Schueller, W. Scheithauer, C. Zielinski, F. Herbst, T. Gruenberger (2008)Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 11
A. Pool, Z. Lalmahomed, Y. Özbay, J. Wilt, A. Eggermont, J. Jzermans, C. Verhoef (2010)‘Staged’ liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome
Colorectal Disease, 12
M. Stimpfl, D. Tong, B. Fasching, Eva Schuster, A. Obermair, S. Leodolter, R. Zeillinger (2002)Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 8 7
B. Vogelstein, E. Fearon, S. Hamilton, S. Kern, Antonette Preisinger, M. Leppert, Y. Nakamura, R. White, A. Smits, J. Bos (1988)Genetic alterations during colorectal-tumor development.
The New England journal of medicine, 319 9
H. Chang, W. Leeper, G. Chan, D. Quan, D. Driman (2012)Infarct-like Necrosis: A Distinct Form of Necrosis Seen in Colorectal Carcinoma Liver Metastases Treated With Perioperative Chemotherapy
The American Journal of Surgical Pathology, 36
E. Giovannucci (2002)Modifiable risk factors for colon cancer.
Gastroenterology clinics of North America, 31 4
S. Soker, S. Takashima, H. Miao, G. Neufeld, M. Klagsbrun (1998)Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor
S. Zakaria, J. Donohue, F. Que, M. Farnell, C. Schleck, D. Ilstrup, D. Nagorney (2007)Hepatic Resection for Colorectal Metastases: Value for Risk Scoring Systems?
Annals of Surgery, 246
E. Cutsem, F. Rivera, S. Berry, A. Kretzschmar, M. Michael, M. Dibartolomeo, M. Mazier, J. Canon, V. Georgoulias, M. Peeters, J. Bridgewater, D. Cunningham (2009)Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Annals of oncology : official journal of the European Society for Medical Oncology, 20 11
I. Zlobec, R. Steele, L. Terracciano, J. Jass, A. Lugli (2006)Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer
Journal of Clinical Pathology, 60
V. Artigas, Guillermo Marín-Hargreaves, Eugenio Marcuello, Albert Pey, J. González, Manuel Rodríguez, Antonio Moral, J. Monill, J. Sancho, C. Pericay, M. Trias (2007)Resección quirúrgica de metástasis hepáticas de cáncer colorrectal. Experiencia del Hospital de Sant Pau
Cirugia Espanola, 81
R. Adam, V. Delvart, G. Pascal, A. Valeanu, D. Castaing, D. Azoulay, S. Giacchetti, B. Paule, F. Kunstlinger, O. Ghémard, F. Lévi, H. Bismuth (2004)Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival
Annals of Surgery, 240
National Comprehensive Cancer Network. Colon cancer practice guidelines in oncology
S. Lastoria, M. Piccirillo, C. Caracó, G. Nasti, L. Aloj, C. Arrichiello, E. Castelguidone, F. Tatangelo, A. Ottaiano, R. Iaffaioli, F. Izzo, G. Romano, P. Giordano, S. Signoriello, C. Gallo, F. Perrone (2013)Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab
The Journal of Nuclear Medicine, 54
É. Terrebonne, Denis Smith, Y. Bécouarn, P. Michel, R. Guimbaud, D. Auby, A. Cunha, A. Ravaud, M. Rouyer, A. Fourrier-Réglat (2010)Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study.
Journal of Clinical Oncology, 28
Y. Kishi, D. Zorzi, C. Contreras, D. Maru, S. Kopetz, D. Ribero, M. Motta, N. Ravarino, M. Risio, S. Curley, E. Abdalla, L. Capussotti, J. Vauthey (2010)Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
Annals of Surgical Oncology, 17
B Morgan, AL Thomas, J Drevs, J Hennig, M Buchert, A Jivan (2003)Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies
J Clin Oncol, 21
E. Leitch, M. Chakrabarti, Jem Crozier, RF Mckee, JH Anderson, P. Horgan, DC McMillan (2007)Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer
British Journal of Cancer, 97
R. Adam, G. Pascal, D. Castaing, D. Azoulay, V. Delvart, B. Paule, F. Lévi, H. Bismuth (2004)Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases?
Annals of Surgery, 240
J. Vauthey, T. Pawlik, D. Ribero, Tsung-Teh Wu, D. Zorzi, P. Hoff, H. Xiong, C. Eng, G. Lauwers, M. Mino‐Kenudson, M. Risio, A. Muratore, L. Capussotti, S. Curley, E. Abdalla (2006)Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 13
Yutaka Takahashi, S. Tucker, Y. Kitadai, A. Koura, C. Bucana, K. Cleary, L. Ellis (1997)Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer.
Archives of surgery, 132 5
L. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T.S. Yang, F. Rivera, F. Couture, F. Sirzén, J. Cassidy (2023)Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Journal of Clinical Oncology, 41
E. Botteri, S. Iodice, V. Bagnardi, S. Raimondi, A. Lowenfels, P. Maisonneuve (2008)Smoking and colorectal cancer: a meta-analysis.
JAMA, 300 23
A. Grothey, E. Cutsem, A. Sobrero, S. Siena, A. Falcone, M. Ychou, Y. Humblet, O. Bouché, L. Mineur, C. Barone, A. Adenis, J. Tabernero, T. Yoshino, H. Lenz, R. Goldberg, D. Sargent, F. Cihon, L. Cupit, A. Wagner, D. Laurent (2013)Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
The Lancet, 381
T. Gruenberger, J. Bridgewater, I. Chau, P. Alfonso, M. Rivoire, S. Mudan, S. Lasserre, F. Hermann, D. Waterkamp, René Adam (2015)Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 26 4
G. Folprecht, T. Gruenberger, W. Bechstein, H. Raab, F. Lordick, J. Hartmann, H. Lang, A. Frilling, J. Stoehlmacher, J. Weitz, R. Konopke, C. Stroszczynski, T. Liersch, D. Ockert, T. Herrmann, E. Goekkurt, F. Parisi, C. Köhne (2010)Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
The Lancet. Oncology, 11 1
RA Ezekowitz, JB Mulliken, J Folkman (1992)Interferon alfa-2a therapy for life-threatening hemangiomas of infancy
N Engl J Med, 326
B. Nordlinger, H. Sorbye, B. Glimelius, G. Poston, P. Schlag, P. Rougier, W. Bechstein, J. Primrose, E. Walpole, M. Finch-Jones, D. Jaeck, D. Mirza, R. Parks, M. Mauer, E. Tanis, E. Cutsem, W. Scheithauer, T. Gruenberger (2013)Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
The Lancet. Oncology, 14 12
F. Fraioli, M. Anzidei, F. Zaccagna, M. Mennini, G. Serra, B. Gori, F. Longo, C. Catalano, R. Passariello (2011)Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience.
Radiology, 259 2
Andrew Smith, Shetal Shah, B. Rini, M. Lieber, E. Remer (2010)Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
AJR. American journal of roentgenology, 194 6
J Holash, S Davis, N Papadopoulos, SD Croll, L Ho, M Russell (2002)VEGF-Trap: a VEGF blocker with potent antitumor effects
Proc Natl Acad Sci U S A, 99
P. Ryan, S. Nanji, A. Pollett, M. Moore, C. Moulton, S. Gallinger, M. Guindi (2010)Chemotherapy-induced Liver Injury in Metastatic Colorectal Cancer: Semiquantitative Histologic Analysis of 334 Resected Liver Specimens Shows That Vascular Injury but not Steatohepatitis Is Associated With Preoperative Chemotherapy
The American Journal of Surgical Pathology, 34
M. Gagnon, D. Bielenberg, Z. Gechtman, H. Miao, S. Takashima, S. Soker, M. Klagsbrun (2000)Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity.
Proceedings of the National Academy of Sciences of the United States of America, 97 6
R. Vera, M. Dorronsoro, S. López-Ben, A. Viúdez, B. Queralt, Irene Hernández, M. Ortiz-Duran, C. Zazpe, J. Soriano, I. Amat, J. Cabezón, E. Díaz, A. Codina-Barreras, X. Hernández-Yagüe, A. Quera, J. Figueras (2014)Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab
Clinical and Translational Oncology, 16
D. Hicklin, L. Ellis (2005)Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 5
J. Primrose, S. Falk, M. Finch-Jones, J. Valle, D. O’reilly, A. Siriwardena, J. Hornbuckle, M. Peterson, M. Rees, T. Iveson, T. Hickish, R. Butler, L. Stanton, Elizabeth Dixon, L. Little, M. Bowers, S. Pugh, O. Garden, D. Cunningham, T. Maughan, J. Bridgewater (2014)Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
The Lancet. Oncology, 15 6
H. Ohtani (2007)Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.
Cancer Immunity Archive, 7
Hassan Malik, K. Prasad, K. Halazun, A. Aldoori, A. Al-mukhtar, D. Gomez, J. Lodge, G. Toogood (2007)Preoperative Prognostic Score for Predicting Survival After Hepatic Resection for Colorectal Liver Metastases
Annals of Surgery, 246
T. Aloia, M. Sebagh, M. Plasse, V. Karam, F. Lévi, S. Giacchetti, D. Azoulay, H. Bismuth, D. Castaing, R. Adam (2006)Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 31
D. Dindo, N. Demartines, P. Clavien (2004)Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey
Annals of Surgery, 240
I. Maroulis, D. Karavias, D. Karavias (2011)General principles of hepatectomy in colorectal liver metastases
Techniques in Coloproctology, 15
M. Cross, J. Dixelius, Taro Matsumoto, L. Claesson-Welsh (2003)VEGF receptor signal transduction.
Science's STKE : signal transduction knowledge environment, 2001 112
A. Parikh, F. Fan, W. Liu, S. Ahmad, O. Stoeltzing, N. Reinmuth, D. Bielenberg, C. Bucana, M. Klagsbrun, L. Ellis (2004)Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis.
The American journal of pathology, 164 6
S. Iwatsuki, I. Dvorchik, J. Madariaga, J. Marsh, F. Dodson, A. Bonham, D. Geller, T. Gayowski, J. Fung, T. Starzl (1999)Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system.
Journal of the American College of Surgeons, 189 3
O. Stoeltzing, Wenbiao Liu, N. Reinmuth, A. Parikh, S. Ahmad, Y. Jung, F. Fan, L. Ellis (2003)New Approaches to the Treatment of Hepatic Malignancies Angiogenesis and Antiangiogenic Therapy of Colon Cancer Liver Metastasis
Annals of Surgical Oncology, 10
J. Lordan, N. Karanjia, N. Quiney, W. Fawcett, T. Worthington (2009)A 10-year study of outcome following hepatic resection for colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 35 3
N. Ferrara (2000)Vascular endothelial growth factor and the regulation of angiogenesis.
Recent progress in hormone research, 55
LM McShane, DG Altman, W Sauerbrei, SE Taube, M Gion, GM Clark (2005)Reporting recommendations for tumor marker prognostic studies (REMARK)
J Natl Cancer Inst, 97
T. Gruenberger, D. Arnold, L. Rubbia-Brandt (2012)Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival.
Surgical oncology, 21 4
J. Ichante, A. Adenis, E. François, E. Boucher, J. Pignon, M. Ychou, J. Pierga, C. Montotot-Grillo, T. Conroy, M. Ducreux (2011)6094 POSTER Impact of Early Tumour Shrinkage on Long-term Outcome in Metastatic Colorectal Cancer (mCRC) Treated With 5FU+lrinotecan+Leucovorin (FOLFIRI) or Capecitabine+lrinotecan XELIRI Plus Bevacizumab
European Journal of Cancer, 47
M. Karoui, C. Penna, Mohamed Amin-Hashem, E. Mitry, S. Benoist, B. Franc, P. Rougier, B. Nordlinger (2006)Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases
Annals of Surgery, 243
Colon cancer practice guidelines in oncology
M. MD, Frcsc MD, Frcsc MD, Frcsc MD, Frcsc MD, MSc MD (2006)Survival After Hepatic Resection for Colorectal Metastases: A 10-Year Experience
Annals of Surgical Oncology, 13
C. Bokemeyer, I. Bondarenko, A. Makhson, J. Hartmann, J. Aparicio, F. Braud, S. Donea, H. Ludwig, G. Schuch, C. Stroh, A. Loos, A. Zubel, P. Koralewski (2009)Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 5
P. García, S. Alvarez, A. Muñoz, P. Lopez, M. Riesco, J. Alfonso, M. Martín (2011)Neoadjuvant bevacizumab treatment for colorectal liver metastasis: A retrospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 4_suppl
M. Klinger, Sandra Eipeldauer, S. Hacker, B. Herberger, D. Tamandl, M. Dorfmeister, C. Koelblinger, B. Gruenberger, T. Gruenberger (2009)Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 35 5
M. Anzidei, A. Napoli, F. Zaccagna, G. Cartocci, L. Saba, G. Menichini, B. Marincola, E. Marotta, Luisa Mare, C. Catalano, R. Passariello (2011)Liver Metastases From Colorectal Cancer Treated With Conventional and Antiangiogenetic Chemotherapy: Evaluation With Liver Computed Tomography Perfusion and Magnetic Resonance Diffusion-Weighted Imaging
Journal of Computer Assisted Tomography, 35
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar (2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
The New England journal of medicine, 350 23
More than 50 % of patients with colorectal cancer develop liver metastases. Surgical resection is the only available treatment that improves survival in patients with colorectal liver metastases (CRLM). New antiangiogenic targeted therapies, such as bevacizumab, aflibercept, and regorafenib, in combination with neoadjuvant and conversion chemotherapy may lead to improved response rates in this population of patients and increase the proportion of patients eligible for surgical resection. The present review discusses the available data for antiangiogenic targeted agents in this setting. One of these therapies, bevacizumab, which targets the vascular endothelial growth factor (VEGF) has demonstrated good results in this setting. In patients with initially unresectable CRLM, the combination of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab has led to high response and resection rates. This combination is also effective for patients with unresectable CRLM. Moreover, the addition of bevacizumab to chemotherapy in the neoadjuvant setting of liver metastasis has a higher impact on pathological response rate. This drug also has a manageable safety profile, and according to recent data, bevacizumab may protect against the sinusoidal dilation provoked in the liver by certain cytotoxic agents. In phase II trials, antiangiogenic therapy has demonstrated benefits in the presurgical treatment of CRLM and may represent a new treatment pathway for these patients.
Targeted Oncology – Springer Journals
Published: Mar 11, 2015
Access the full text.
Sign up today, get DeepDyve free for 14 days.